Adjuvant bevacizumab in patients with melanoma at high risk...

The Lancet Oncology 2014 / 05 Vol. 15; Iss. 6

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study

Corrie, Pippa G, Marshall, Andrea, Dunn, Janet A, Middleton, Mark R, Nathan, Paul D, Gore, Martin, Davidson, Neville, Nicholson, Steve, Kelly, Charles G, Marples, Maria, Danson, Sarah J, Marshall, Ern
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
15
Language:
english
Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(14)70110-X
Date:
May, 2014
File:
PDF, 361 KB
english, 2014
Conversion to is in progress
Conversion to is failed